Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Open Access
- 18 March 2010
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 59 (6), 1338-1348
- https://doi.org/10.2337/db09-1324
Abstract
OBJECTIVE: The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive. RESEARCH DESIGN AND METHODS: To assess the metabolic effects of chronic inhibition of the mTORC1/S6K1 pathway, rats were treated with rapamycin (2 mg/kg/day) or vehicle for 15 days before metabolic phenotyping. RESULTS: Chronic rapamycin treatment reduced adiposity and fat cell number, which was associated with a coordinated downregulation of genes involved in both lipid uptake and output. Rapamycin treatment also promoted insulin resistance, severe glucose intolerance, and increased gluconeogenesis. The latter was associated with elevated expression of hepatic gluconeogenic master genes, PEPCK and G6Pase, and increased expression of the transcriptional coactivator peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) as well as enhanced nuclear recruitment of FoxO1, CRTC2, and CREB. These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop. CONCLUSIONS: These findings unravel a novel mechanism by which mTORC1/S6K1 controls gluconeogenesis through modulation of several key transcriptional factors. The robust induction of the gluconeogenic program in liver of rapamycin-treated rats underlies the development of severe glucose intolerance even in the face of preserved hepatic insulin signaling to Akt and despite a modest reduction in adiposity.This publication has 51 references indexed in Scilit:
- Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 PathwayPLOS ONE, 2009
- mTOR complex 2 in adipose tissue negatively controls whole-body growthProceedings of the National Academy of Sciences of the United States of America, 2009
- Depot-specific effects of the PPARγ agonist rosiglitazone on adipose tissue glucose uptake and metabolismJournal of Lipid Research, 2009
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009
- A PGC-1α-O-GlcNAc Transferase Complex Regulates FoxO Transcription Factor Activity in Response to GlucosePublished by Elsevier BV ,2009
- Thematic Review Series: Glycerolipids. Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolismJournal of Lipid Research, 2008
- A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchangeNature, 2008
- Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent mannerProceedings of the National Academy of Sciences, 2008
- Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2Nature, 2007
- Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistanceProceedings of the National Academy of Sciences, 2007